With AAV alternative and DNA writing tech, a new hub-and-spoke startup wants to ‘democratize’ gene therapies

Lei Lei Wu

News Reporter

When Adrian Woolfson was head of R&D at Sangamo, he began contemplating starting his own company. His goal? Solve some of the key challenges plaguing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With AAV alternative and DNA writing tech, a new hub-and-spoke startup wants to ‘democratize’ gene therapies

Lei Lei Wu

News Reporter

Sign up to read this article for free.

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Pfizer partners with two more Flagship biotechs on obesity, cancer

Novo and Viking present new MASH data, but analysts remain confident in Madrigal's Rezdiffra

Are programs with compounded GLP-1s safe for your population?

With AAV al­ter­na­tive and DNA writ­ing tech, a new hub-and-spoke start­up wants to ‘de­moc­ra­tize’ gene ther­a­pies

Lei Lei Wu

News Reporter

Sign up to read this article for free.

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

With AAV alternative and DNA writing tech, a new hub-and-spoke startup wants to ‘democratize’ gene therapies

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Pfizer partners with two more Flagship biotechs on obesity, cancer

Novo and Viking present new MASH data, but analysts remain confident in Madrigal's Rezdiffra

Are programs with compounded GLP-1s safe for your population?